MX2015008288A - Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. - Google Patents

Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.

Info

Publication number
MX2015008288A
MX2015008288A MX2015008288A MX2015008288A MX2015008288A MX 2015008288 A MX2015008288 A MX 2015008288A MX 2015008288 A MX2015008288 A MX 2015008288A MX 2015008288 A MX2015008288 A MX 2015008288A MX 2015008288 A MX2015008288 A MX 2015008288A
Authority
MX
Mexico
Prior art keywords
viral disease
amelioration
prevention
treatment
pyridone derivatives
Prior art date
Application number
MX2015008288A
Other languages
English (en)
Spanish (es)
Inventor
Helmut Buschmann
Sung-Sau So
Andrea Wolkerstorfer
Oliver Szolar
Stephen Cusack
Mark Smith
Norbert Handler
Ronald Charles Hawley
Original Assignee
Savira Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savira Pharmaceuticals Gmbh filed Critical Savira Pharmaceuticals Gmbh
Publication of MX2015008288A publication Critical patent/MX2015008288A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
MX2015008288A 2013-01-08 2014-01-07 Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. MX2015008288A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750023P 2013-01-08 2013-01-08
PCT/EP2014/050166 WO2014108407A1 (en) 2013-01-08 2014-01-07 Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (1)

Publication Number Publication Date
MX2015008288A true MX2015008288A (es) 2016-06-02

Family

ID=50070508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008288A MX2015008288A (es) 2013-01-08 2014-01-07 Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.

Country Status (11)

Country Link
US (1) US8952039B2 (enExample)
EP (1) EP2943469A1 (enExample)
JP (1) JP2016508145A (enExample)
KR (1) KR20150103034A (enExample)
CN (1) CN104903294A (enExample)
BR (1) BR112015016184A2 (enExample)
CA (1) CA2894452A1 (enExample)
HK (2) HK1212688A1 (enExample)
MX (1) MX2015008288A (enExample)
RU (1) RU2015125570A (enExample)
WO (1) WO2014108407A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2938877T3 (es) 2015-04-28 2023-04-17 Shionogi & Co Derivados de piridona policíclicos sustituidos y profármacos de los mismos
EP4219508B1 (en) 2015-04-28 2024-06-05 Shionogi & Co., Ltd Substituted polycyclic pyridone derivative and prodrug thereof
CR20180356A (es) 2015-12-15 2018-08-22 Shionogi & Co Un medicamento caracterizado por combinar un inhibidor de la endonucleasa cap-dependiente del virus de la influenza y un fármaco anti-influenza
WO2017106820A1 (en) 2015-12-17 2017-06-22 Thomas Jefferson University Antiviral agents for drug-resistant influenza a
US10889556B2 (en) * 2016-03-08 2021-01-12 The Regents Of The University Of California Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease
NZ791086A (en) 2016-08-10 2025-08-29 Shionogi & Co Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
JP2024522292A (ja) 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのn-(ヒドロキシアルキル(ヘテロ)アリール)テトラヒドロフランカルボキサミド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
JP2007519735A (ja) * 2004-01-30 2007-07-19 メルク エンド カムパニー インコーポレーテッド Hivインテグラーゼ阻害剤として有用であるn−ベンジル−3,4−ジヒドロキシピリジン−2−カルボキサミド及びn−ベンジル−2,3−ジヒドロキシピリジン−4−カルボキサミド化合物
JP4953297B2 (ja) 2004-09-15 2012-06-13 塩野義製薬株式会社 Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
EP2412708A4 (en) * 2009-03-26 2014-07-23 Shionogi & Co SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections

Also Published As

Publication number Publication date
WO2014108407A1 (en) 2014-07-17
CN104903294A (zh) 2015-09-09
RU2015125570A (ru) 2017-02-10
US8952039B2 (en) 2015-02-10
JP2016508145A (ja) 2016-03-17
KR20150103034A (ko) 2015-09-09
CA2894452A1 (en) 2014-07-17
BR112015016184A2 (pt) 2017-07-11
HK1211287A1 (en) 2016-05-20
US20140194476A1 (en) 2014-07-10
EP2943469A1 (en) 2015-11-18
HK1212688A1 (zh) 2016-06-17

Similar Documents

Publication Publication Date Title
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
MX2014014106A (es) Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
HK1211289A1 (en) Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
MX2014014109A (es) Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral.
MX2014003801A (es) Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MX2015008288A (es) Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
PH12019500163A1 (en) Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof
MX2014003803A (es) Derivados de acido heteroarilo hidroxamico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EA033689B9 (ru) Ингибиторы g12c kras
TN2014000436A1 (en) Inhibitors of platelet aggregation
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12019500480A1 (en) Pyridine compound
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
IN2015MN00002A (enExample)
MX2013012588A (es) Inhibidores de cinasa.
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
MX2021005207A (es) Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidina-5-carboxamida.
HK1232227A1 (zh) 作为pi3k抑制剂的喹嗪酮衍生物
EA201692298A1 (ru) Производные карбоксамидов
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.